The safety of antiproliferative agents in newborns is a critical concern. Due to the delicate nature of neonatal physiology, these medications must be used cautiously. Clinical trials and case studies have shown some success, but potential side effects, such as myelosuppression, gastrointestinal disturbances, and immunosuppression, must be carefully monitored. The long-term impact on growth and development is still under investigation.
